Gaithri Ramanathan, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 751 Route 73 S, Evesham, NJ 08053 Phone: 856-396-3183 |
Dr. Maya Panchal, OD Optometrist Medicare: Medicare Enrolled Practice Location: 748 Route 73 S Ste C, Evesham, NJ 08053 Phone: 856-596-5925 |
Eyes On Evesham, L.l.c. Optometrist Medicare: Medicare Enrolled Practice Location: 751 Route 73 S, Evesham, NJ 08053 Phone: 856-396-3183 Fax: 855-595-2570 |
News Archive
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patient has been dosed in its open-label phase IIa trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis of the shoulder, also known as Frozen Shoulder syndrome.
Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.
Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are also inherently resistant to many other common antibiotics, which limits the available options in finding alternative treatments to resistant TB strains.
The new Jefferson Vascular Center at Thomas Jefferson University Hospital offers an integrated, multidisciplinary approach to the diagnosis, management and treatment of vascular diseases (diseases of blood vessels) and thrombotic (blood-clotting) disorders all under one roof.
An extremely small RNA molecule created by a University of Colorado at Boulder team can catalyze a key reaction needed to synthesize proteins, the building blocks of life. The findings could be a substantial step toward understanding "the very origin of Earthly life," the lead researcher contends.
› Verified 3 days ago